Treatment as Prevention¨

The spread of hepatitis C virus (HCV) in North America peaked between 1940 and 1965, according to research published in the March 30 advance edition of Lancet Infectious Diseases. The investigators attribute the rapid spread of the infection to hospital transmissions and reuse of medical injection equipment rather than risky behaviors such as injection drugs, […]

The FDA has approved Descovy, a fixed-dose combination tablet containing emtricitabine and tenofovir alafenamide, for the treatment of HIV, according to the drug’s manufacturer. Descovy (emtricitabine/tenofovir alafenamide [F/TAF]; Gilead Sciences) is administered as a single oral tablet taken daily in combination with other antiretroviral agents. The formulation includes 200 mg emtricitabine and 25 mg tenofovir

Segment from 1:40:13 – 1:49:33

TORONTO – Canadian researchers have determined the peak of the hepatitis C epidemic in North America occurred about 15 years earlier than previously believed, suggesting it wasn’t youthful indiscretions that put baby boomers at a high risk for the disease. And that means, say researchers, that all those who belong to the post-Second World War

A novel investigation into the North American spread of hepatitis C virus permits blame shifting, which the authors Jeffrey Joy and colleagues hope will increase the number of baby boomers who undergo testing. The medical community can now take its share of the responsibility for hepatitis C virus infection in its conversations with the 1945-65

As a youth growing up in Chicago, Phill Wilson had a Cuban fetish. The Spanish literature major romanticized the island nation, which was off-limits to U.S. travelers since the Cuban Missile Crisis of 1963. A half-century later, Wilson – now the out president of the Los Angeles-based Black AIDS Institute -would find himself en route

Imagine seeing a patient every eight weeks for a few quick injections into the buttocks that could prevent HIV between appointments. That’s the promise of the ÉCLAIR trial of the investigational integrase strand transfer inhibitor cabotegravir, which had its phase-2 results unveiled at CROI 2016 in February. ÉCLAIR was one of two trials of long-acting